FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Executive Summary
Attorneys Sasinowski and Varond write that in some cases weak clinical evidence on the surrogate endpoint was not a barrier, but strong findings on unmet need and rarity usually are necessary for accelerated approval.
You may also be interested in...
US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.
US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
Proposed assessment system upgrade would add automation to potentially reduce refuse-to-file actions and review cycles.
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.